MedTrace Logo

A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients

NCT03035032 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2024-11-26

Study results available
· View outcomes & findings →

Summary

The objective of this study was to evaluate the safety profile of ELIGARD® in ethnic Asian prostate cancer patients.

Conditions

Interventions

DRUG

Leuprolide

Subcutaneous Injection

Sponsors & Collaborators

  • Astellas Pharma Singapore Pte. Ltd.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Astellas Pharma Inc

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-23
Primary Completion
2019-11-19
Completion
2019-11-19
FDA Drug
Yes

Countries

  • Hong Kong
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Taiwan
  • Thailand
  • Vietnam

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03035032 on ClinicalTrials.gov